Hypotyreose er indberettet som en bivirkning hos 7 patienter (4%) i de 2 cytokin- refraktære mRCC - undersøgelser; hos 9 patienter (2%) på SUTENT og hos 1 patient (< 1%) i IFN- α armen i den behandlingsnaive mRCC- undersøgelse.
Hypothyroidism was reported as an adverse event in 7 patients (4%) across the two cytokine-refractory MRCC studies; in nine patients (2%) on SUTENT and one patient (< 1%) in the IFN-α arm in the treatment- naïve MRCC study.